Back to search

Peptide record

TPDB02993

FLAK 26 Ac Antibacterial Anticancer Antifungal Toxicity standard
17 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB02993
FLAK 26 Ac
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF Antifungipept CAFPdb dbAMP
standard
No
A 17-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
FAKKLAKLAKKLAKLAL
Physicochemical Analysis
C90H163N23O18
RNDCEQGHIMPSTWYV
K
1855.43
11.21
6
0
11
+6
1.16
0.435
144.12
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
5
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
5
L
6
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 5 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 6 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
17
C90H163N23O18
1855.43
11.21
+6
1.16
0.435
Free
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 11 records
Evidence 1 Activity

Activity

LD50
LD50 =105 µg/ml
Anticancer
105 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =100 µg/ml
Anticancer
100 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =140 µg/ml
Anticancer
140 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =127 µg/ml
Anticancer
127 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =66 µg/ml
Anticancer
66 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =170 µg/ml
Anticancer
170 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

50% Hemolysis
Toxicity
112.5 µM
Hemolytic Cytotoxic
50% Hemolysis | 112.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Designing Anticancer Peptides by Constructive Machine Learning. | ChemMedChem | 2018
Evidence 8 Activity

Activity

LD50
Toxicity
8 µg/mL
Cytotoxic
LD50 | 8 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 9 Activity

Activity

LD50
Toxicity
64 µg/mL
Cytotoxic
LD50 | 64 | µg/mL | target cell: Human leukocytes

Target

Human leukocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 10 Activity

Activity

LD50
Toxicity
93 µg/mL
Cytotoxic
LD50 | 93 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 11 Activity

Activity

50% Hemolysis
Toxicity
390 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 390 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005